STAT Webinar: Will biosimilars ever realize their promise in the U.S. market?

Policymakers in Washington are pushing biosimilars as a way to introduce competition and restrain drug price increases, and have recently released a slate of policies intended to reinvigorate the biologics market. But many biosimilars have had difficulty making it into the U.S. market, or obtaining FDA approval — even as they’re being sold (and approved) in Europe. Register for our Nov. 13 webinar to join STAT senior writer and Pharmalot columnist Ed Silverman and STAT Washington correspondent Nick Florko as they discuss why.